Twelve Points Wealth Management LLC Purchases 53 Shares of Danaher Co. (NYSE:DHR)

Twelve Points Wealth Management LLC increased its position in shares of Danaher Co. (NYSE:DHR) by 2.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,662 shares of the conglomerate’s stock after acquiring an additional 53 shares during the quarter. Twelve Points Wealth Management LLC’s holdings in Danaher were worth $740,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. CWM LLC boosted its holdings in Danaher by 14.6% during the first quarter. CWM LLC now owns 21,912 shares of the conglomerate’s stock worth $5,472,000 after buying an additional 2,799 shares during the last quarter. Ferguson Wellman Capital Management Inc. boosted its stake in Danaher by 9.1% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 1,519 shares of the conglomerate’s stock worth $379,000 after acquiring an additional 127 shares during the last quarter. Montecito Bank & Trust grew its holdings in Danaher by 10.7% during the first quarter. Montecito Bank & Trust now owns 4,023 shares of the conglomerate’s stock valued at $1,005,000 after purchasing an additional 388 shares during the period. Wedmont Private Capital increased its stake in Danaher by 14.6% in the first quarter. Wedmont Private Capital now owns 4,391 shares of the conglomerate’s stock valued at $1,097,000 after purchasing an additional 561 shares in the last quarter. Finally, McLean Asset Management Corp bought a new stake in Danaher in the first quarter valued at approximately $207,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on DHR shares. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Robert W. Baird boosted their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI raised their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research report on Friday, September 6th. Finally, Bank of America raised their target price on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $282.12.

Danaher Trading Down 1.7 %

Shares of NYSE:DHR opened at $267.99 on Thursday. The company has a 50-day simple moving average of $270.53 and a 200 day simple moving average of $259.65. The company has a market capitalization of $198.50 billion, a P/E ratio of 45.42, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s revenue was down 2.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.05 EPS. Sell-side analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.